9-Plex · MS-Focused

Th1/Th17 · Chemokine · BBB Trafficking

MSD Multiple Sclerosis Research 9-Plex Panel

A pathway-targeted multiplex panel designed specifically for multiple sclerosis research — simultaneously quantify nine key cytokines and chemokines driving Th1/Th17-mediated inflammation, blood-brain barrier immune cell trafficking, and CNS demyelination from a single 25 µL sample.

Multiple sclerosis is characterized by peripheral immune cell infiltration across the blood-brain barrier, driven by a complex network of chemokine gradients and polarized T-cell responses. This 9-plex panel captures the core cytokine and chemokine axes implicated in MS pathogenesis — from T-cell survival signals (IL-7) and Th1/Th17 polarization (IL-12/IL-23p40) to the chemokine trafficking routes that guide autoreactive lymphocytes into the CNS (IP-10, MCP-1, MIP-3α, Fractalkine). Each analyte was selected based on published MS biomarker literature, providing a hypothesis-informed, research-ready panel rather than a generic cytokine screen.

Inquire About the MS 9-Plex Panel View Panel Composition

Multiple Sclerosis — A Cytokine-Driven Autoimmune Disease of the CNS

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system in which peripherally activated autoreactive T cells breach the blood-brain barrier (BBB) and initiate inflammatory lesions. The immunological hallmark of MS is a disrupted balance between pro-inflammatory effector T-cell subsets (Th1, Th17) and regulatory T cells (Treg), orchestrated by a network of cytokines and chemokines that govern immune cell activation, polarization, and CNS trafficking. Understanding this cytokine-chemokine network is central to MS biomarker research and therapeutic development.

 Why a Pathway-Targeted Panel for MS Research
Th1/Th17 axis captured: IL-12/IL-23p40 is the shared subunit of IL-12 (drives Th1) and IL-23 (drives Th17) — both implicated in MS pathogenesis and targeted by approved disease-modifying therapies.
BBB trafficking chemokines: IP-10 (CXCL10), MCP-1 (CCL2), MIP-3α (CCL20), and Fractalkine (CX3CL1) represent the key chemotactic routes by which autoreactive lymphocytes, monocytes, and Th17 cells cross the BBB into the CNS parenchyma.
T-cell survival and recruitment: IL-7 promotes survival and clonal expansion of autoreactive T cells; CTACK and GRO-α direct immune cell homing to inflammatory sites.
Treatment monitoring relevance: Several panel analytes are modulated by MS disease-modifying therapies (DMTs), supporting use as pharmacodynamic biomarkers in therapeutic research.
Literature-grounded selection: Each of the 9 analytes has published evidence for altered CSF and/or serum levels in MS research cohorts versus controls — this is not a generic cytokine panel but a hypothesis-driven MS research tool.

Research Applications

Disease activity monitoring — track cytokine and chemokine fluctuations associated with relapsing vs. progressive MS phases in longitudinal observational cohort studies.
DMT pharmacodynamics — quantify treatment-associated shifts in Th1/Th17/chemokine profiles as secondary endpoints in investigational MS therapeutic trials.
Relapse prediction research — evaluate cytokine signatures preceding clinical and radiographic MS relapses in prospectively collected sample sets.
Progressive MS research — characterize the inflammatory microenvironment in primary and secondary progressive MS, where compartmentalized CNS inflammation may differ from peripheral signatures in relapsing disease.
Comparative neuroimmunology — profile MS-specific cytokine patterns against other neuroinflammatory conditions (NMOSD, MOGAD, autoimmune encephalitis) for differential signature research.

Panel Composition — 9 Analytes Targeting MS Pathogenic Pathways

Each analyte was selected based on published evidence for involvement in MS immunopathogenesis — spanning T-cell biology, chemokine-driven CNS trafficking, and inflammatory amplification.

#	Analyte	Alternative Name	Biological Role in MS	Research Relevance
1	IL-7	Interleukin-7	T-cell survival & homeostasis	Promotes survival and clonal expansion of autoreactive T cells; elevated in MS CSF; genetic variants in IL-7R are among the strongest non-HLA MS risk loci identified by GWAS
2	CTACK	CCL27	T-cell skin/CNS homing	CCR10 ligand; elevated in MS CSF and associated with intrathecal inflammation; implicated in memory T-cell trafficking to inflammatory sites
3	Fractalkine	CX3CL1	Neuron-microglia signaling	Unique dual-domain chemokine/adhesion molecule; mediates neuron-glia communication; altered expression in MS lesions; shed form promotes microglial activation
4	GRO-α	CXCL1	Neutrophil & myeloid recruitment	CXCR2 ligand; upregulated in MS lesions and CSF; contributes to BBB disruption via neutrophil and myeloid cell recruitment to the CNS
5	IL-12/IL-23p40	IL12B	Th1 & Th17 polarization	Shared subunit of IL-12 (Th1 driver) and IL-23 (Th17 driver); target of ustekinumab; elevated in active MS; central node in MS inflammatory cascade linking innate to adaptive immunity
6	IP-10	CXCL10	Th1 cell CNS trafficking	CXCR3 ligand; most consistently elevated chemokine in MS CSF across published studies; drives Th1 lymphocyte migration across the BBB into CNS parenchyma
7	MCP-1	CCL2	Monocyte/macrophage recruitment	CCR2 ligand; regulates monocyte and macrophage infiltration into MS lesions; altered CSF levels correlate with lesion activity on MRI in published research
8	MIP-1β	CCL4	Macrophage & T-cell chemoattraction	CCR5 ligand; elevated in MS CSF; produced by activated macrophages and microglia within MS plaques; amplifies intrathecal inflammatory loops
9	MIP-3α	CCL20	Th17 cell CNS entry	CCR6 ligand; principal chemoattractant for Th17 cells — the dominant pathogenic T-cell subset in MS; expressed by BBB endothelial cells and astrocytes under inflammatory conditions; facilitates Th17 crossing of the BBB

Panel composition may be customized via U-PLEX to add, remove, or substitute analytes. Contact us to configure a panel aligned with your specific MS research hypotheses. All services are for research use only.

T-Cell Biology

IL-7 drives autoreactive T-cell survival; IL-12/IL-23p40 polarizes Th1 and Th17 effector subsets — together capturing the T-cell-intrinsic drivers of MS immunopathology at the initiation and amplification stages.

BBB Trafficking

IP-10, MCP-1, MIP-3α, MIP-1β, GRO-α, and Fractalkine represent the major chemokine axes directing lymphocytes and myeloid cells across the blood-brain barrier — the critical step in MS lesion formation.

CNS Compartmentalization

CTACK and Fractalkine report on intrathecal immune activity and neuron-glia inflammatory cross-talk within the CNS — complementing the peripherally focused trafficking chemokines.

Assay Performance — Quality Metrics

Representative performance data for the MS Research 9-Plex Panel.

<12% CV

Intra-Plate Precision
Median across all 9 analytes, 3 QC levels

<18% CV

Inter-Plate Precision
Day-to-day reproducibility

3–4 logs

Dynamic Range
Per analyte; pg/mL sensitivity

Standard Curves

9 independent 8-point calibration curves per plate with R² ≥ 0.99 for each analyte. Multi-analyte calibrator blend with lot-specific concentration assignments.

Cross-Reactivity Control

Each antibody pair screened against all other 8 panel analytes at physiologically relevant concentrations. Cross-reactivity <0.5% for all pairwise combinations.

Spike Recovery

80–120% recovery for each analyte spiked at low, medium, and high concentrations into CSF and plasma matrices. Matrix-specific recovery data provided with each project.

How MSD Delivers the MS 9-Plex

Why electrochemiluminescence is the right platform for pathway-targeted multiplex panels in neuroimmunology research.

Analytical Requirements for MS Biomarker Multiplexing

MS biomarker research demands simultaneous measurement of multiple interacting cytokines and chemokines that span a wide concentration range — from low pg/mL chemokines (MIP-3α, IP-10) to higher-abundance cytokines (IL-7). Running separate single-plex assays for 9 analytes consumes precious CSF sample volume, introduces cross-assay variability, and fails to capture the network-level relationships that are central to MS immunopathogenesis. Bead-based multiplex platforms, while offering higher plex levels, introduce spectral overlap artifacts at this density and can produce inconsistent chemokine measurements in the low pg/mL range where many MS-relevant analytes circulate.

ECL Detection Advantages for MS Biomarker Panels

1. Spatial Spot Separation — Chemokine-Clean Signals

Each analyte occupies a discrete electrode spot within the well, electrically addressed in sequence. No fluorescent bead spectral overlap means no cross-talk between structurally similar chemokines (e.g., MIP-1β vs. MCP-1), delivering cleaner low-pg/mL chemokine quantification than bead-based platforms.

2. SULFO-TAG ECL Detection — CSF-Ready

Non-enzymatic, chemically stable SULFO-TAG labels emit light only upon electrical stimulation. Zero autofluorescence from CSF matrix — a key advantage for intrathecal MS biomarker research, where CSF protein composition can interfere with fluorescence-based detection.

3. 3–4 Log Dynamic Range per Spot

Accommodates the full physiological range of MS-relevant cytokines — from low pg/mL chemokines to ng/mL acute-phase cytokines — without requiring sample dilution adjustments that introduce pre-analytical variability.

4. Pre-Configured V-PLEX Format

Manufacturer-pre-coated plates with lot-controlled reagents; each lot qualified against reference standards. Long-term lot reservation available for longitudinal MS cohort studies spanning years of sample collection.

MS 9-Plex Panel Specifications

TechnologyMSD V-PLEX

Plex Level9 analytes per well

Sample Volume25 µL per well

Plate Format96-well MULTI-ARRAY

Read Time~70 seconds per plate

Sensitivitypg/mL range (analyte-dependent)

Dynamic Range3–4 logs per analyte

CalibratorMulti-analyte blend, 8 points

Intra-Assay CV (median)<12%

Inter-Assay CV (median)<18%

Recommended MatrixCSF, Serum, EDTA Plasma

CustomizationU-PLEX: add NfL, GFAP, or other markers

Pathway-Targeted vs. Broad Profiling in MS Research

MS Focus 9-Plex

Lit. Evidence 9-Plex

Hypothesis 9-Plex

Discovery 37-Plex

Cost 9-Plex

The 9-plex is optimal for MS-focused studies with pre-specified hypotheses about Th1/Th17/chemokine pathways. For broader discovery or characterization of the full neuroinflammatory milieu, the Neuroinflammation 37-Plex provides extended coverage. The two panels can be used sequentially — 37-plex for discovery, 9-plex for focused validation.

MS 9-Plex Panel Service Details

Service package, sample requirements, and deliverables.

Service Package

Item	Full Service	Kit Only
Sample Processing	Included	— Self-run
Standard Curve	8-point, all 9 analytes	Reagents provided
QC Samples	3 levels, duplicate	— User-prepared
Multi-Analyte Data Report	Full 9-plex quantitative report	— Self-analysis
Pathway Analysis	Th1/Th17 indices, chemokine profiles	— Self-analysis
Raw Data	Included	— Instrument-dependent

For Research Use Only. Not for diagnostic procedures.

Sample Submission Requirements

Preferred MatrixCSF (for direct CNS inflammatory profiling), EDTA Plasma

AcceptableSerum (note: clotting process releases platelet-derived cytokines; maintain consistent matrix within study)

Typical Sample Volume50–200 µL per aliquot. Minimum 25 µL per well. Exact volume requirements depend on replicate strategy — we'll advise during study design.

Collection (CSF)Polypropylene tube → centrifuge at 2,000×g/10 min/4°C → aliquot into polypropylene cryovials → freeze immediately at −80°C

Collection (Blood)EDTA tube (or serum separator if serum is required) → centrifuge at 1,500×g/10 min/4°C → aliquot → −80°C

Critical NoteFor longitudinal MS studies — consistent collection timing relative to DMT dosing (trough vs. peak) and clinical events (relapse, corticosteroid administration) is essential for interpretable cytokine data.

ShippingDry ice, overnight courier

DocumentationSample manifest form with clinical metadata fields for MS-specific variables (provided upon project initiation)

How to Get Started

Consult

Tell us about your MS research program — disease subtype (RRMS, SPMS, PPMS), DMT status, sample type (CSF vs. blood), and analytes of primary interest. We'll confirm the 9-plex is the optimal configuration for your hypotheses.

Ship

Send your CSF or blood samples on dry ice following our MS-specific pre-analytical guidelines. We provide collection protocols optimized for cytokine stability and MS-relevant clinical metadata forms.

Receive Data

Receive your complete 9-plex data package — quantitative report with Th1/Th17 indices and chemokine trafficking profiles, QC metrics, and methods documentation formatted for MS research publications.

Running paired CSF-serum sampling? Ask about our combined matrix analysis — measure the 9-plex in both CSF and serum from the same timepoint to evaluate peripheral-CNS cytokine concordance in your MS cohort.

MS Cytokine Profiling: MSD 9-Plex vs Other Approaches

Platform comparison for pathway-targeted multiplex cytokine and chemokine analysis in MS research.

Feature	MSD V-PLEX 9-Plex	Luminex xMAP	Olink Proteomics (PEA)	Individual ELISA (×9)
Plex Level	9-plex	Up to 50-plex	Up to 96-plex	9 separate kits
Detection	ECL (spatial addressing)	Fluorescent beads (spectral)	DNA oligo + qPCR/NGS	Colorimetric/fluorescent
Chemokine Low-pg/mL Performance	Excellent — background-free ECL	Moderate — spectral overlap at low signal	Very good — proximity-dependent specificity	Variable — kit-dependent
CSF Compatibility	High — no autofluorescence	Moderate — matrix effects possible	High — low matrix interference	Moderate — high volume needed
Sample Volume (for 9 analytes)	25 µL total	25–50 µL	<10 µL	900 µL (100 µL × 9)
Read Time	~70 seconds/plate	~45–60 min/plate	External readout required	9 × ~2 hours
Pre-Configured MS Panel	Yes (V-PLEX)	Custom premix required	Pre-designed panels available	Individual kit selection
Best Research Fit	Pathway-targeted MS studies with direct, rapid chemokine readout	Large plex screening; budget-constrained projects	Discovery proteomics; ultra-high multiplex	Single-analyte validation

The MSD 9-plex is optimized for pathway-directed MS research — delivering cleaner low-pg/mL chemokine signals than bead-based platforms and substantially lower sample consumption than running 9 separate ELISAs, critical for precious CSF samples in MS cohort studies.

What You Receive

Comprehensive quantitative report — concentration for all 9 analytes, organized by biological pathway (T-cell, chemokine, CNS compartment) with Th1/Th17 balance indices (Excel + PDF)
Raw ECL data — per-well, per-spot signal values for all 9 analytes, plate layout maps, and individual standard curve plots — directly compatible with independent statistical analysis
Pathway-level summary — integrated chemokine trafficking profiles, Th1/Th17 polarization ratios, and CNS vs. peripheral inflammatory indices
QC documentation — per-analyte intra/inter-plate CV, spike recovery, cross-reactivity verification, LOD/LLOQ confirmation
Methods summary — formatted for direct inclusion in MS-focused research manuscript Methods sections
Post-delivery discussion — scheduled call with the lead scientist to review MS-specific cytokine profiles and their biological interpretation in your cohort context

Why Our Clients Choose Us

Literature-grounded MS panel design — each of the 9 analytes was selected based on published MS biomarker evidence, not generic cytokine catalog availability; the panel captures the Th1/Th17/chemokine axes most consistently implicated in MS immunopathology
Chemokine-optimized ECL detection — MSD's background-free electrochemiluminescence is particularly advantageous for low-pg/mL chemokine quantification (IP-10, MIP-3α, MIP-1β) where fluorescence-based platforms contend with CSF autofluorescence and spectral overlap
25 µL for 9 analytes — CSF-friendly — the entire 9-plex consumes less sample volume than a single ELISA well, preserving precious longitudinal CSF aliquots for additional biomarker analyses, neurofilament testing, or biobank retention
Paired CSF-serum analysis capability — the same platform quantifies the 9-plex in both matrices with validated performance, enabling direct peripheral-CNS cytokine concordance analysis within your MS cohort
DMT-aware study design support — our scientific team considers your cohort's treatment landscape (DMT class, timing, corticosteroid exposure) when advising on sampling strategy and data interpretation, ensuring treatment-associated cytokine modulation is accounted for in your analysis

Supporting Publications

Published research supporting cytokine and chemokine profiling in multiple sclerosis.

Comabella M, Montalban X (2014) The Lancet Neurology. 13(1):113–126. "Body fluid biomarkers in multiple sclerosis." DOI: 10.1016/S1474-4422(13)70245-X · PMID: 24331797

Dendrou CA, Fugger L, Friese MA (2015) Nature Reviews Immunology. 15(9):545–558. "Immunopathology of multiple sclerosis." DOI: 10.1038/nri3871 · PMID: 26250739

Sørensen TL, Tani M, Jensen J, et al. (1999) The Journal of Clinical Investigation. 103(6):807–815. "Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients." DOI: 10.1172/JCI5150 · PMID: 10079101

Gregory AP, Dendrou CA, Attfield KE, et al. (2012) Nature. 488(7412):508–511. "TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis." DOI: 10.1038/nature11307 · PMID: 22801493

Kebir H, Kreymborg K, Ifergan I, et al. (2007) Nature Medicine. 13(10):1173–1175. "Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation." DOI: 10.1038/nm1651 · PMID: 17828272

Disanto G, Barro C, Benkert P, et al. (2017) Annals of Neurology. 81(6):857–870. "Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis." DOI: 10.1002/ana.24954 · PMID: 28512753

References for informational context. For Research Use Only.

MS 9-Plex Panel FAQ

Is this panel validated for clinical diagnostic use?

No. This MS Research 9-Plex Panel is manufacturer-validated for research use only (RUO). It is suitable for preclinical studies, cohort research, biomarker discovery, and therapeutic development applications. It is not validated for clinical diagnostic procedures, patient management decisions, or as a standalone screening tool. All data is reported with the explicit disclaimer that it should not be used as the sole basis for clinical decision-making.

Why a focused 9-plex instead of a broader cytokine panel for MS research?

This 9-plex is a hypothesis-driven panel — each analyte was selected based on published MS biomarker literature rather than generic catalog availability. The advantages over a broader panel include: (1) Cost-efficiency — you're not paying for 20+ analytes with no established MS relevance; (2) Statistical power — fewer analytes means fewer multiple-testing corrections, preserving statistical power for your primary hypotheses; (3) Literature precedent — each analyte has published MS cohort data to contextualize your findings; (4) Focused biology — the panel tells a coherent immunological story (Th1/Th17 activation → chemokine-directed BBB trafficking → CNS inflammation) rather than producing an unfocused list of values. For discovery-phase studies where broad profiling is preferred, the Neuroinflammation 37-Plex is available as a complementary option.

Which sample matrix should I use — CSF or blood — for MS cytokine profiling?

The optimal matrix depends on your research question. CSF directly reflects the intrathecal inflammatory environment and is recommended for studies focused on CNS-compartmentalized inflammation, meningeal immune activity, and correlation with MRI lesion activity. Blood (EDTA plasma or serum) captures the peripheral immune activation that precedes and sustains CNS infiltration, and is more practical for frequent longitudinal sampling. Many MS research programs collect paired CSF and blood at selected timepoints — our platform supports both matrices with validated performance. Regardless of matrix choice, consistency within the study is essential, and collection timing relative to DMT dosing and clinical events (relapse, corticosteroid treatment) should be standardized. Contact us during study design for matrix-specific guidance.

Can this panel be used to monitor treatment response to disease-modifying therapies?

Yes, the 9-plex is well-suited for pharmacodynamic biomarker research in MS therapeutic studies. Several panel analytes are directly modulated by approved DMT classes: IL-12/IL-23p40 is the target of ustekinumab; IP-10 and MCP-1 are modulated by natalizumab (which blocks VLA-4-mediated lymphocyte trafficking); interferon-β therapies broadly alter chemokine expression profiles. For DMT research, we recommend: (1) standardized sampling time relative to DMT dosing schedule; (2) documentation of concomitant corticosteroid use (which can transiently suppress multiple panel analytes); (3) consideration of pre- vs. post-dose sampling design to capture pharmacodynamic effect magnitude. All applications are research use only — this panel is not validated for clinical treatment monitoring.

Can I add neurodegeneration markers like NfL or GFAP to this panel?

Yes. Through MSD's U-PLEX custom platform, neurodegeneration markers such as NfL (neurofilament light — a leading MS biomarker for axonal injury and treatment response), GFAP (astrocyte reactivity), and total Tau can be added to the 9-plex, creating a combined neuroinflammation + neurodegeneration panel for MS research. This is a popular configuration for MS cohort studies that want to capture both the inflammatory driver (cytokines/chemokines) and its neurodegenerative consequence (NfL release) from the same sample. Contact our scientific team to design a custom panel configuration.

What clinical metadata should I collect alongside samples for optimal data interpretation?

For MS cytokine studies, we recommend collecting the following metadata for each sample: (1) MS subtype (RRMS, SPMS, PPMS) and disease duration; (2) Current DMT (drug, dose, dosing schedule, time since last dose); (3) Recent relapse history (date of last clinical relapse and/or gadolinium-enhancing MRI lesion); (4) Recent corticosteroid use (drug, dose, date of last administration — corticosteroids can transiently suppress multiple cytokines); (5) EDSS or equivalent disability score at the sampling timepoint; (6) Sample collection time of day (some cytokines exhibit diurnal variation). We provide a standardized MS-specific sample manifest form to facilitate metadata capture. All services are provided under a research-use-only framework.

Inquiry Basket